Acute myocardial infarction: Recommendations for medical management and primary angioplasty

Postgraduate Medicine

Volumn 102, Issue 3, 1997, Pages 159-175

  Whisenant, Brian K ^a   Wolfe, Christopher L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANISTREPLASE; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; GLYCERYL TRINITRATE; HEPARIN; HIRUDIN; LAMIFIBAN; LISINOPRIL; MAGNESIUM; NIFEDIPINE; NITRIC ACID DERIVATIVE; PLASMINOGEN ACTIVATOR; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; STREPTOKINASE; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR DERIVATIVE; UNINDEXED DRUG; UROKINASE; VERAPAMIL;

ACUTE HEART INFARCTION; ANTICOAGULANT THERAPY; ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESEARCH; FIBRINOLYTIC THERAPY; HEPARINIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

EID: 0030964673     PISSN: 00325481     EISSN: None     Source Type: Journal    
DOI: 10.3810/pgm.1997.09.319     Document Type: Article

References (29)

1. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. J Am Coll Cardiol 1988; 12(6 Suppl A):3A-13A
2. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992;327(4):248-54
3. Roberts R, Rogers WJ, Mueller HS, et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) II-B Study. Circulation 1991;83(2): 422-37
4. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet 1994;343(8893):311-22 [Erratum, Lancet 1994;343(8899):742]
5. Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993;342(8874):759-66
6. GISSI-2 and International Study Group. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto. Six-month survival in 20,891 patients with acute myocardial infarction randomized between alteplase and streptokinase with or without heparin. Eur Heart J 1992;13(12):1692-7
7. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339(8796):753-70
8. The GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329(10): 673-82
9. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy: results from the GUSTO-1 trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation 1996;94(8):1826-33
10. MacMahon S, Collins R, Knight C, et al. Reduction in major morbidity and mortality by heparin in acute myocardial infarction. (Abstr) Circulation 1988; 78(4 Suppl 2):98
11. Antraan EM. Hirudin in acute myocardial infarction: safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994;90(4):1624-30
12. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995;345(8951): 669-85
13. Gruppo ltaliano per lo Studio della Sopravvivenza nell'infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994;343(8906): 1115-22
14. Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction: results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992;327(10): 678-84
15. Ryan TJ, Anderson JL, Antman EM, et al. ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1996;28(5):1328-428
16. Woods KL, Fletcher S, Hoffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1992;339(8809):1553-8
17. Antman EM. Magnesium in acute MI: timing is critical. (Editorial) Circulation 1995;92(9):2367-72
18. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988; 319(7):385-92
19. The RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94(5): 891-8
20. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. International Joint Efficacy Comparison of Thrombolytics. Lancet 1995;346(8971):329-36 [Erratum, Lancet 1995;346(8980):980]
21. Benedict CR, Refino CJ, Keyt BA, et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995;92(10):3032-40
22. The EPIC Investigation. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med l994;330(14):956-61
23. Canadian Lamifiban Study. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina. Circulation 1996;94(5):899-905
24. European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89(2):596-603
25. Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94(5):911-21
26. Mayo Coronary Care Unit and Catheterization Laboratory Groups. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative treatment for myocardial infarction. N Engl J Med 1993; 328(10):685-91
27. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med l993;328(10):680-4
28. Primary Angioplasty in Myocardial Infarction Study Group. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. N Engl J Med 1993;328(10):673-9
29. Myocardial Infarction Triage and Intervention Investigators. A comparison of thrombolytic therapy with primary coronary angioplasty for acute myocardial infarction. N Engl J Med 1996;335(17):1253-60